Archive | Oncology

Pembrolizumab, PD1, Keytruda, Biologic Models

Pembrolizumab bound to PD1

3D print of Pembrolizumab (KEYTRUDA) bound to PD-1. Model available in multiple materials and sizes. “Pembrolizumab (formerly MK-3475and lambrolizumab, trade name Keytruda)[1] is a humanized antibodyused in cancer immunotherapy. It destroys a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1(PD-1) receptor. The drug was initially used in treating metastatic melanoma.” Protein […]

Continue Reading
pembrolizumab_3Dprint

Comparative Analysis Pembrolizumab and PD-1 Receptor Binding Properties

Immunotherapy is the treatment of cancer using antibodies that target points of failure in the life cycle of cancer cells. Many of these therapies involve altering monoclonal antibodies to target specific proteins associated to different types of cancer. Understanding the binding properties of these proteins is of utmost importance. Pembrolizumab, an igG4 Monoclonal Antibody Pembrolizumab […]

Continue Reading
sandstone_egfr_inactivet_gloss1

Inactive EGFR Tyrosine Kinase

This is a 3D print of X-ray crystallography dataset 4HJO, the Crystal Structure of the Inactive EGFR Tyrosine Kinase Domain with Erlotinib. 4TRP Protein Description “Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through […]

Continue Reading